[Antitumor effects of recombinant quail vascular endothelial growth factor receptor 2, as a vaccine, combined with cisplatin on LL/2 tumor model in mice].
OBJECTIVE
Bio-chemotherapy is a new trend in cancer therapy. Antiangiogenic therapy represents a new strategy of tumor biotherapy. This study was designed to explore antitumor effect of recombinant quail vascular endothelial growth factor receptor 2 (qVEGFR) combined with cisplatin.


METHODS
Lewis lung carcinoma model (LL/2) was established in C57BL/6 mice. Seven days after inoculation of tumor cells, mice were randomized into combination group, qVEGFR group, chemotherapy group, and normal saline (NS) group (10 mice/group), and received relevant treatments. Tumor growth, survival rate of mice, and side effects were observed. Anti-VEGFR-2 antibody-producing B cells (APBCs) was detected by enzyme-linked immunospot (ELISPOT), microvessel density (MVD) of tumor was detected by immunohistochemistry, and tumor cell apoptosis was also detected.


RESULTS
Tumor volume of mice was obviously smaller in combination group than in NS group. Complete regression of tumor growth was observed in 3 of the 10 mice in combination group. Seventy days after inoculation of tumor cells, survival rate of mice was significantly higher in combination group than in qVEGFR, cisplatin, and NS groups (90% vs. 60%, 0%, and 0%, P < 0.05). APBCs counts were (156.8+/-19.3)/10(6) spleen cells in combination group, and (143.6+/-18.6)/10(6) spleen cells in qVEGFR group. MVD was significantly lower in combination group than in cisplatin, and NS groups (11.4+/-1.3 vs. 33.4+/-4.5, and 45.5 +/- 4.5, P < 0.01), MVD in qVEGFR group was 16.4+/-1.6. Tumor cell apoptosis was significantly higher in combination group than in qVEGFR, cisplatin, and NS groups [(36.2+/-3.5)% vs. (15.4+/-2.4)%, (17.6+/-2.6)%, and (4.1+/-1.4)%, P < 0.05].


CONCLUSIONS
The combination therapy of qVEGFR and cisplatin has synergistic antitumor effect.
Hou
Jian-Mei
JM
National Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, P. R. China.
Liu
Ji-Yan
JY
Yang
Li
L
Zhao
Xia
X
Tian
Ling
L
Lei
Song
S
Mao
Yong-Qiu
YQ
Wen
Yan-Jun
YJ
Wei
Yu-Quan
YQ
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D017209:Apoptosis / Q000187:drug effects; D019496:Cancer Vaccines / Q000627:therapeutic use*; D018827:Carcinoma, Lewis Lung / Q000098:blood supply / Q000188:drug therapy* / Q000473:pathology; D045744:Cell Line, Tumor; D002945:Cisplatin / Q000627:therapeutic use*; D004357:Drug Synergism; D006801:Humans; D051379:Mice; D008810:Mice, Inbred C57BL; D008833:Microcirculation / Q000187:drug effects / Q000473:pathology; D011784:Quail; D011897:Random Allocation; D011994:Recombinant Proteins / Q000235:genetics / Q000627:therapeutic use; D040301:Vascular Endothelial Growth Factor Receptor-2 / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D019496:Cancer Vaccines; D011994:Recombinant Proteins; D040301:Vascular Endothelial Growth Factor Receptor-2; D002945:Cisplatin